Poliovirus Receptor antibody (PerCP-Cy5.5)

Catalog No. ABIN2659976

This anti-Poliovirus Receptor antibody is a Rat Monoclonal antibody detecting Poliovirus Receptor in ELISPOT (Detection) and ELISA (Detection). Suitable for Mouse.

Quick Overview for Poliovirus Receptor antibody (PerCP-Cy5.5) (ABIN2659976)

Target: Poliovirus Receptor (PVR)

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This Poliovirus Receptor antibody is conjugated to PerCP-Cy5.5

Application: ELISpot (Detection) (ELISPOT (Detection)), ELISA (Detection)

Clone: TX56

Product Details anti-Poliovirus Receptor Antibody (PerCP-Cy5.5)

Purification: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for Poliovirus Receptor

Target: Poliovirus Receptor (PVR)

Alternative Name: CD155

Background: Mouse CD155, also known as homolog of polivirus receptor (PVR), is the founding member of a subfamily of immunoglobulin-like adhesion receptors (nectins). Mouse CD155 is expressed on a wide variety of cells of hematopoietic origin apart from its existence on the epithelial cells. The engagement of CD155 with CD226 and CD96 induces cytotoxicity of NK cells and CTL.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Cancer Immune Checkpoints, SARS-CoV-2 Protein Interactome